Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions Patents (Class 424/1.11)
  • Patent number: 11453721
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 27, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos, Alison Crawford
  • Patent number: 11433023
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 6, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11426487
    Abstract: The present invention relates to implants comprising a deformable body formed of a polymer comprising functional groups capable of cross-linking to form a cross-link; said body provided in a first configuration which is cross-linked to a second configuration upon application of a selected stimuli; wherein said selected stimuli causes said cross-linking of said functional groups.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: August 30, 2022
    Assignee: SetBone Medical Ltd.
    Inventors: Nimrod Kaufmann, Royi Kaufmann
  • Patent number: 11419934
    Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: August 23, 2022
    Assignee: Oncotelic Therapeutics, Inc.
    Inventors: David J. Chaplin, Kimberly Perkins
  • Patent number: 11419954
    Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 23, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
  • Patent number: 11413359
    Abstract: The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: August 16, 2022
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Samuel Achilefu, Kexian Liang, Rui Tang
  • Patent number: 11414455
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 16, 2022
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDA
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 11406724
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: August 9, 2022
    Assignee: ACTINIUM PHARMACEUTICALS, INC.
    Inventors: Kaushik J. Dave, Shubh D. Sharma
  • Patent number: 11406720
    Abstract: The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 9, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Thomas D. Wang, Juan Zhou
  • Patent number: 11365219
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 21, 2022
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
  • Patent number: 11358982
    Abstract: Provided herein are methods for iodinating biomolecules, including proteins and peptides. The methods can be used to successfully and efficiently iodinate biomolecules under relatively mild reaction conditions. As a consequence, the methods described herein can be used to iodinate biomolecules that include, for example, an oxidatively unstable moiety (e.g., an optical dye) without adversely impacting the oxidatively unstable moiety.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 14, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Krishan Kumar
  • Patent number: 11358962
    Abstract: The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6 have any of the values defined in the specification.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 11357874
    Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: June 14, 2022
    Inventor: Stanley Satz
  • Patent number: 11344623
    Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: May 31, 2022
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Charity Wayua
  • Patent number: 11344634
    Abstract: Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: May 31, 2022
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Galia Blum, Darya Tsivrkun, Hanmant Gaikwad
  • Patent number: 11344639
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 31, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen, David K. Leung
  • Patent number: 11344635
    Abstract: Macrocyclic complexes and macrocyclic compounds. The macrocyclic complexes or macrocyclic compounds have a TACN moiety with one or more amine group(s) or a O- or S-substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(III) atom coordinated to the TACN moiety. The macrocyclic complexes can be used in imaging methods.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: May 31, 2022
    Assignee: The Research Foundation for the State University of New York
    Inventors: Janet R. Morrow, Zuiru Lin, Didar Asik, Eric M. Snyder, Elizabeth A. Kras
  • Patent number: 11331393
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 17, 2022
    Assignee: Blaze Bioscience, Inc.
    Inventors: Julia E. Novak, Natalie Winblade Nairn, Dennis M. Miller
  • Patent number: 11324826
    Abstract: Multifunctional compositions and methods are provided for therapeutic treatment of bacteria and cancers and for fluorescence diagnosis. Systems generate in situ reactive oxygen species such as singlet oxygen (1O2), hydroxyl radical (OH) and Juglone, and other chemotherapeutic agents. Methods provided selectively produce greater amounts of one reactive oxygen species over others. Variations are effective in aerobic, anaerobic or H2O2 rich environments and in presence of, or absence of, light. In H2O2 rich environment in absence of light, variations decompose H2O2 into O2 gas to remove excess H2O2 for elimination of hypoxic environment. Variations are formed of porphyrins, naphthalene derivatives, and metal ions, for illustration, free base tetrakis Ar substituted porphyrine core without metal or halide substitution but having hydroxyphenyl and alkyl pyridyl substituents at meso positions combined with dihydroxynaphthalene and +3 hydrated metal ions.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: May 10, 2022
    Inventor: Matibur Rahaman Zamadar
  • Patent number: 11324837
    Abstract: Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 10, 2022
    Assignee: Portland State University
    Inventor: Marilyn Mackiewicz
  • Patent number: 11311637
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Curasight A/S
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • Patent number: 11306072
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 19, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Patent number: 11278723
    Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 22, 2022
    Assignee: NANOBIOTIX S.A.
    Inventors: Marie-Edith Meyre, Agnès Pottier, Laurent Levy
  • Patent number: 11278627
    Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: March 22, 2022
    Assignee: MC SAF
    Inventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
  • Patent number: 11268105
    Abstract: The present invention encompasses compositions and methods to rejuvenate cells by, expanding the replicative life span of the cells for, e.g., use in regenerative therapies. Specifically, the methods and compositions of the present invention increase the proliferation capacity and differentiation capacity and plasticity of cells.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 8, 2022
    Assignee: CarryGenes Bioengineering
    Inventors: Edward Perkins, Amy Greene, Dominique Broccoli
  • Patent number: 11260136
    Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 1, 2022
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, Bayer AS
    Inventors: Lars Linden, Alan Cuthbertson
  • Patent number: 11260127
    Abstract: A system for delivering a therapeutic agent to cell or tissue of a subject includes a mesoporous silica iron oxide nanoparticle with one or more therapeutic agents that are contained in a mesoporous silica layer of the nanoparticle and a remote radiofrequency (RF) energy source for applying RF energy to the nanoparticle effective to release the one or more therapeutic agents from the nanoparticle by mechanical tumbling and/or vibration of the nanoparticle, wherein release of the one or more therapeutic agents not caused by a hyperthermic response of the nanoparticle to the RF energy.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 1, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Efstathios Karathanasis, Watuthentrige Pubudu M. Peiris, Vindya Perera, Lisa Bauer
  • Patent number: 11241511
    Abstract: Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising the HER3 imaging agents are also provided.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 8, 2022
    Assignee: The General Hospital Corporation
    Inventors: Umar Mahmood, Benjamin Larimer
  • Patent number: 11234936
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent iransfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: February 1, 2022
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • Patent number: 11235076
    Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: February 1, 2022
    Assignees: Fred Hutchinson Cancer Research Center, The Regents of the Universitv of California
    Inventors: Roland K. Strong, Peter Rupert, Rebecca J. Abergel, Ilya Captain, Gauthier J P Deblonde
  • Patent number: 11224666
    Abstract: A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Douglas Pennington, Paul Sorajja
  • Patent number: 11213511
    Abstract: Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: January 4, 2022
    Assignee: Syntekabio, Inc.
    Inventors: Jong Sun Jung, Jong Hui Hong, Dong Myung Kim, Bong Hwan Park, Young Bae Ryu, Hyung Jun Kwon, In Chul Lee, Ji Young Park
  • Patent number: 11213596
    Abstract: An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Richard Lee Tadsen, Andrew J. Ro, Joel T. Eggert, Douglas Pennington, Paul Sorajja, Sarah Melissa Gruba, Tatyana Dyndikova
  • Patent number: 11198909
    Abstract: Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 14, 2021
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventors: Ralf Hoffmann, Eveline Den Biezen-Timmermans, Dianne Arnoldina Margaretha Wilhelmina Van Strijp, Anne Godefrida Catharina Van Brussel, Marcia Alves De Inda, Johannes Baptist Adrianus Dionisius Van Zon, Janneke Wrobel
  • Patent number: 11193932
    Abstract: The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: December 7, 2021
    Assignee: VisEn Medical, Inc.
    Inventor: Narasimhachari Narayanan
  • Patent number: 11192894
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 7, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Anton Shakhmin, Joel R. Walker, Wenhui Zhou
  • Patent number: 11185710
    Abstract: A ferrofluid chamber has a housing that is adapted to be coupled to a component that generates a magnetic field. The housing may be disposed around the component so as to insulate a noise-producing region of the component. The magnetic field may be of sufficient strength to stimulate anatomical tissue. In addition, a ferrofluid may be disposed within the housing for cooling the component.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: November 30, 2021
    Assignee: Neuronetics, Inc.
    Inventors: Mark Edward Riehl, Kenneth Ghiron
  • Patent number: 11181524
    Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 23, 2021
    Assignee: Metabolomycs, Inc
    Inventors: Robert Nagourney, Ismael Silva, Paulo D'Amora
  • Patent number: 11179039
    Abstract: An elongated device and a system that at the same time allow acquisition of temperature-related data of high spatial and temporal resolution from hollow structures together with other relevant data of physical or chemical variables. In a preferred embodiment infrared or visible light sensors are used to obtain thermal or color images from the inner surface during imposed change of the temperature in the lumen of the hollow structure. The disclosure makes it possible to evaluate thermal variations when the inner surface returns to pre-change thermal conditions. High-resolution data can be obtained with the disclosure. The disclosure further includes a system with rotators, injection pumps, a control unit and display operably coupled to one or more of the data acquisition and processing system.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: November 23, 2021
    Assignee: GI Bionics LLC
    Inventor: Hans Gregersen
  • Patent number: 11168115
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: November 9, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
  • Patent number: 11167050
    Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: November 9, 2021
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Yasushi Arano, Tomoya Uehara, Hiroyuki Suzuki
  • Patent number: 11162141
    Abstract: The invention relates, in part, to compounds, compositions, and methods to assess molecular characteristics papillary microcarcinoma (PMC) of the thyroid and indicators of indolent compared to aggressive PMC of the thyroid. In addition, the invention relates, in part, to methods of assessing characteristics of microRNAs associated with PMC of the thyroid.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 2, 2021
    Assignee: University of Vermont and State Agricultural College
    Inventors: Frances Carr, Nikoletta Sidiropoulos
  • Patent number: 11162937
    Abstract: The invention relates to methods and compositions for the selection of patients for therapy with an anti-inflammatory drug. More particularly, the invention relates to compositions comprising folate-imaging agent conjugates for the selection of patients for therapy with an anti-inflammatory drug, and methods and uses therefor.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: November 2, 2021
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Lindsay E. Kelderhouse
  • Patent number: 11155553
    Abstract: Ligands that are based on the pyclen macrocycle that are reinforced, which are useful for complexing elements such as radioelements and/or elements with magnetic properties.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: October 26, 2021
    Assignees: GUERBET, UNIVERSITE DE BRETAGNE OCCIDENTALE, Centre national de la recherche scientifique
    Inventors: Raphaël Tripier, Olivier Rousseaux, Mariane Le Fur, Maryline Beyler, Olivier Fougère, Gwladys Nizou
  • Patent number: 11150242
    Abstract: Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device. Also provided are pharmaceutical compositions, kits, and packages containing such devices. Additional embodiments relate to methods for making the devices, compositions, and kits/packages. Further embodiments relate to methods for using the devices, compositions, and/or kits in the diagnosis or therapy of diseases such as autoimmune diseases or cancers.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 19, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Omar Abdel-Rahman Ali, David J. Mooney
  • Patent number: 11142508
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 12, 2021
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Patent number: 11136383
    Abstract: Disclosed are compositions and methods for modulating the activity of TGF-?. More particularly, compositions and methods for modulating the release of active TGF-? from an LRRC33-TGF-? prodomain-TGF-? ternary complex are provided, as are and methods of treatment based upon such modulation.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 5, 2021
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan Springer, Chafen Lu, Yan Qin, Aiping Jiang
  • Patent number: 11129838
    Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 28, 2021
    Assignee: Unity Biotechnology, Inc.
    Inventors: Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
  • Patent number: 11123445
    Abstract: A flexible brachytherapy device includes a bioresorbable carrier matrix structure comprising a plurality of radio-isotope particles and having opposite first and second surfaces. The bioresorbable carrier matrix structure degrades, when implanted at a wound site, at a rate such that the bioresorbable carrier matrix structure has a half-life that is longer than a half-life of the plurality of radio-isotope particles. A hydrophilic substrate located adjacent to the first surface of the bioresorbable carrier matrix structure degrades, when implanted at the wound site, at a rate faster than the bioresorbable carrier matrix structure. A hydrogel substrate located adjacent to the second surface of the bioresorbable carrier matrix structure shields radioactivity and degrades at a rate such that the hydrogel substrate has a half-life that is longer than the half-life of the plurality of radio-isotope particles.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 21, 2021
    Assignee: Margin-Clear Pty Ltd
    Inventors: David Burnett, Daniel Croagh, Mehrdad Nikfarjam
  • Patent number: 11116994
    Abstract: The invention relates to a patch (2) with at least one filler and at least one active ingredient, wherein the local distribution of the active ingredient or ingredients within the patch (2) takes place dependent on the morphology, anatomy and physiology of the lesion (1) to be treated.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 14, 2021
    Inventors: Ali Pashazadeh, Nathan Castro, Dietmar W. Hutmacher, Michael Friebe, Axel Boese